| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aaf24f86cfe5e082438ba5a77529780a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf6f92674d7e77b6d01795ac1c0aeff1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa6a8dbd6467e560cd0ec019fe7d722a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81b3cc82cb921a25ab72129dc4de1d93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea22f87249dc1fefd88ef229a4017eac |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2001-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0e28f71908cf800b1575f0a4efeccf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_affd70a8beb5a8ad7f03e789b48c43df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f135574618e0232e4deadc5510876bbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae7fc558176f5a54eddc481b35de0a1b |
| publicationDate |
2003-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0236100-A9 |
| titleOfInvention |
Controlled release metformin compositions |
| abstract |
A composition and methods thereof for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a one-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8911781-B2 |
| priorityDate |
2000-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |